Overview

A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy

Status:
Active, not recruiting

Trial end date:
2022-07-22

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate both the safety and tolerability of up to 4 dosing cycles of TAR-200 for 21 days per dosing cycle in the induction period.

Phase:

Phase 1

Details

Lead Sponsor:

Janssen Research & Development, LLC
Taris Biomedical LLC

Treatments:

Gemcitabine